Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis
about
Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patientsTherapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.Comparative efficacy of switching to natalizumab in active multiple sclerosis.Translation of the Medical Fear Survey to Serbian: psychometric properties.Bridging the species divide: transgenic mice humanized for type-I interferon response.Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.Defining secondary progressive multiple sclerosis.The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.Contribution of different relapse phenotypes to disability in multiple sclerosis.Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.Defining reliable disability outcomes in multiple sclerosis.Management of multiple sclerosis patients in central European countries: current needs and potential solutions.Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.Risk of relapse phenotype recurrence in multiple sclerosis.
P2860
Q33764067-9743310B-B30A-429B-91DB-0F92F995FEEFQ34064026-1763273B-F838-4DA5-8934-CD3B44E979BAQ35469575-74BA9C5D-9C08-480E-8CA5-0250F94FAC21Q37357611-36FF68DA-D033-4B5F-B17F-5E1BF0C7B754Q37458573-43C3DEBE-C021-47FA-9159-744DED2D9F94Q37684523-CAA206E2-8911-494F-A5E4-A5B2C4D38FFBQ38843046-F370CCBA-7B54-4175-885D-2B9D2B7E46FCQ40710140-51D8F893-E7D1-48B7-8286-3C7003ACD404Q40724148-306DCCCE-F69E-4DBC-9A1B-4F12B1F6A1F7Q41721827-20FF1C3A-3E04-4496-9E09-5247B299E032Q47986992-ABA6F025-904D-4676-ADCA-2C569165DC22Q52149517-D0300185-D680-42FF-AAEF-7466B4B7AA7FQ52365115-DAF33F43-F28B-44F3-9D3E-4A7E620D49D4Q53078951-B550504B-0F5D-47A6-AB8C-F1EEBC276AE0Q53090722-86E594CA-461A-406D-9BF9-DF537F07386F
P2860
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Persistence on therapy and pro ...... dosages for multiple sclerosis
@ast
Persistence on therapy and pro ...... dosages for multiple sclerosis
@en
Persistence on therapy and pro ...... dosages for multiple sclerosis
@nl
type
label
Persistence on therapy and pro ...... dosages for multiple sclerosis
@ast
Persistence on therapy and pro ...... dosages for multiple sclerosis
@en
Persistence on therapy and pro ...... dosages for multiple sclerosis
@nl
prefLabel
Persistence on therapy and pro ...... dosages for multiple sclerosis
@ast
Persistence on therapy and pro ...... dosages for multiple sclerosis
@en
Persistence on therapy and pro ...... dosages for multiple sclerosis
@nl
P2093
P2860
P50
P1433
P1476
Persistence on therapy and pro ...... dosages for multiple sclerosis
@en
P2093
Aldo Savino
Bhim Singhal
Cameron Shaw
Celia Oreja-Guevara
Daniele La Spitaleri
Dieter Poehlau
Edgardo Cristiano
Eli Skromne
Elizabeth Alejandra Bacile Bacile
P2860
P304
P356
10.1371/JOURNAL.PONE.0063480
P407
P50
P577
2013-05-21T00:00:00Z